Tagged with CRO

Spain Alfonso García Cañamaque, CEO of León Research, gives an overview of the Spanish clinical research ecosystem and the challenges facing CROs. Also, he explains the differentiating factor of the company and internationalization strategy moving forward as they position themselves as the partner of choice.   One of our challenges is…

Korea Ji-Young Lee, senior director clinical operations, and general management & business administration Korea of PAREXEL Korea discusses the strengths of Korea’s clinical research environment, and how PAREXEL can leverage its technological platform to differentiate itself from the other international CROs conducting global studies in Korea.   Korea manages to combine…

Korea Ten of the top contract research organizations (CROs) currently operating in South Korea, as selected by KoNECT, the Korea National Enterprise for Clinical Trials. Six domestic firms and four international operators make up the top 10.   Made with Visme Infographic Maker     To find out more about Korea’s…

China George Lee, vice-president of clinical operations and country leader of PAREXEL in China, discusses the impact of the recent ownership and management changes of the group, the value that PAREXEL can bring to Chinese biotechs and how the company is uniquely positioned to compete against both local and global CROs.…

China Brian Mi, president of IQVIA Greater China, shares IQVIA’s leadership position in China in both the commercial and R&D space, building on both IMS Health and Quintiles’ market positioning in China prior to the merger; the CORETM components of IQVIA’s competitive advantage and their transformation into a Human Data Science…

Korea Syneos Health, established through a merger in 2017, has held a foothold in Korea through its legacy organisations for over 10 years. Sora Lee, general manager of Syneos Korea, provides her assessment of the impact of the merger. She also comments on Syneos Health’s MoU with KoNECT (Korea National Enterprise…

China Dr Yangzhou Wang, chief operations officer of Crown Bioscience (CrownBio), shares the new era of development for the company following its acquisition by a Japanese industrial conglomerate in December 2017; CrownBio’s biology-driven deep expertise in oncology drug discovery and development and how it will continue to drive the company’s growth;…

China Dr Dan Zhang, CEO of Fountain Medical Development (FMD), details the transformation China’s recent membership at the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) will bring to the drug development and clinical research landscape in China, the pressures and opportunities local companies…

Spain Joan Puig de Dou, CEO of Kymos Pharma, a Spanish analytical CRO, shares his insights in the changing dynamics of the industry and explains how remaining independent in the face of industry consolidation is a strategic priority to leverage both quality and specialization for the company’s clients.   When[biosimilars] come…

Korea Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical research environment over the past four years, the need to foster local CROs if the government is to truly embrace innovation, and the cultural differences in…

Turkey Sule Mene, co-founder, president and CEO of Mene Health Group, shares with PharmaBoardroom the journey of her company starting as the first government-approved CRO of Turkey, its parallel growth alongside the increasingly prominent clinical trial environment of the country, evolution to becoming a value chain group of companies in clinical…

Korea Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu assesses the changing environment for clinical research in Korea and offers her view on the successes and scope for improvement…